CanSino Biologics, Inc. Class H (HK:6185)
:6185
Top Page
CanSino Biologics, Inc. Class H
(6185)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$32.00
▼(-28.79% Downside)
Action:ReiteratedDate:04/08/26
The score is held back primarily by weak cash-flow quality and an expensive valuation (very high P/E). Technicals also lean bearish with the stock below key moving averages and a negative MACD, partially offset by an improving balance sheet and a return to net profitability in 2025.
Positive Factors
Balance-sheet strength
A large equity base and materially reduced debt improve financial flexibility and lower refinancing risk. This stronger leverage profile supports continued investments in manufacturing and R&D, and gives the company capacity to absorb shocks while pursuing long-cycle vaccine programs and tenders.
Negative Factors
Weak cash generation
Persistently negative free cash flow despite an OCF recovery means the company has yet to demonstrate self-funding for capex and pipeline spend. Ongoing cash deficits increase reliance on external financing, raising dilution or debt risk and constraining long-term investment flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
A large equity base and materially reduced debt improve financial flexibility and lower refinancing risk. This stronger leverage profile supports continued investments in manufacturing and R&D, and gives the company capacity to absorb shocks while pursuing long-cycle vaccine programs and tenders.
Read all positive factors
CanSino Biologics, Inc. Class H (6185) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$13.05B
Dividend YieldN/A
Average Volume (3M)609.75K
Price to Earnings (P/E)292.7
Beta (1Y)1.44
Revenue Growth29.21%
EPS Growth80.37%
CountryHK
Employees1,105
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.06
Shares Outstanding132,670,900
10 Day Avg. Volume458,410
30 Day Avg. Volume609,752
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)0.00
Price to Sales (P/S)7.64
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.65
Revenue Forecast (FY)HK$1.45B
CanSino Biologics, Inc. Class H Business Overview & Revenue Model
Company Description
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola vir...
How the Company Makes Money
CanSino Biologics primarily makes money by developing, manufacturing, and selling vaccines. Its revenue model is driven mainly by: (1) Product sales: revenue from supplying marketed vaccines to customers such as government/public health procuremen...
CanSino Biologics, Inc. Class H Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
70
Positive
Cash Flow
33
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.03B | 846.34M | 345.18M | 1.03B | 4.30B |
| Gross Profit | 681.82M | 601.91M | -876.02M | -186.61M | 3.00B |
| EBITDA | 23.29M | -134.84M | -1.65B | -1.32B | 1.85B |
| Net Income | 27.15M | -378.88M | -1.48B | -909.43M | 1.91B |
Balance Sheet | |||||
| Total Assets | 7.18B | 7.96B | 9.32B | 11.47B | 11.87B |
| Cash, Cash Equivalents and Short-Term Investments | 2.65B | 3.20B | 4.12B | 5.95B | 7.78B |
| Total Debt | 1.29B | 2.01B | 2.70B | 2.70B | 1.37B |
| Total Liabilities | 2.05B | 3.05B | 4.03B | 4.22B | 3.33B |
| Stockholders Equity | 4.96B | 4.91B | 5.27B | 6.75B | 8.00B |
Cash Flow | |||||
| Free Cash Flow | -152.83M | -626.42M | -1.53B | -2.96B | 811.42M |
| Operating Cash Flow | 32.49M | -168.79M | -916.25M | -1.89B | 2.01B |
| Investing Cash Flow | 355.36M | 3.96M | -449.65M | -1.19B | -2.53B |
| Financing Cash Flow | -703.03M | -334.18M | -7.58M | 854.60M | 1.56B |
CanSino Biologics, Inc. Class H Technical Analysis
Neutral
44.94
Price Trends
34.03
Negative
36.59
Negative
40.81
Negative
Market Momentum
-0.46
Negative
49.33
Neutral
53.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6185, the sentiment is Neutral. The current price of 44.94 is above the 20-day moving average (MA) of 33.21, above the 50-day MA of 34.03, and above the 200-day MA of 40.81, indicating a bearish trend. The MACD of -0.46 indicates Negative momentum. The RSI at 49.33 is Neutral, neither overbought nor oversold. The STOCH value of 53.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6185.
CanSino Biologics, Inc. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$238.33B | 35.71 | 16.09% | 0.97% | 8.68% | 0.82% | |
70 Outperform | HK$31.70B | 11.61 | 14.47% | 4.09% | -0.45% | 9.00% | |
61 Neutral | HK$39.39B | 6.37 | 7.91% | 2.95% | ― | ― | |
59 Neutral | HK$40.34B | 8.90 | 7.89% | 7.15% | 1.13% | -13.53% | |
57 Neutral | HK$76.00B | 14.15 | 7.02% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$13.05B | 292.71 | 0.57% | ― | 29.21% | 80.37% |
* Healthcare Sector Average
HK:6185
CanSino Biologics, Inc. Class H
33.04
5.84
21.47%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
17.21
1.70
10.97%
HK:1513
Livzon Pharmaceutical Group
29.20
4.54
18.40%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
20.80
7.66
58.26%
HK:3320
China Resources Pharmaceutical Group Ltd.
6.27
1.54
32.56%
HK:3692
Hansoh Pharmaceutical Group Company Limited
39.36
18.15
85.57%
CanSino Biologics, Inc. Class H Corporate Events
CanSino Biologics Publishes Audited 2025 Annual Results and Readies Full Report
Mar 30, 2026
CanSino Biologics Inc. has released its audited consolidated annual results for the year ended December 31, 2025, fulfilling disclosure requirements of the Hong Kong Stock Exchange for preliminary annual results announcements. The full annual repo...
CanSino Biologics Sets March 30 Board Meeting to Approve 2025 Results
Mar 17, 2026
CanSino Biologics Inc. has scheduled a board meeting for March 30, 2026 to review and approve the annual financial results of the company and its subsidiaries for the year ended December 31, 2025. The board will also consider the publication of th...
CanSino Biologics Wins PIC/S GMP Nod for Key Conjugate Vaccines
Mar 5, 2026
CanSino Biologics Inc. has obtained a Good Manufacturing Practice certificate under the Pharmaceutical Inspection Co-Operation Scheme for the manufacturing site of its ACYW135 meningococcal conjugate vaccine and 13-valent pneumococcal conjugate va...
CanSino Biologics Swings to Preliminary 2025 Profit on Higher Revenue
Feb 26, 2026
CanSino Biologics reported preliminary 2025 figures showing total revenue of about RMB1.07 billion, up 26.18% year on year, and a swing to net profit attributable to shareholders of roughly RMB27.87 million from a significant loss a year earlier. ...
CanSino Wins China Nod to Extend Use of Menhycia Pediatric Vaccine
Feb 24, 2026
CanSino Biologics Inc. has received approval from China’s National Medical Products Administration for a supplemental drug application expanding the age indication of its Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, Menhycia...
CanSino Biologics Forecasts 2025 Revenue Growth and Return to Profit
Jan 27, 2026
CanSino Biologics has issued a forecast for 2025 indicating that revenue is expected to rise to between RMB1.04 billion and RMB1.08 billion, representing year-on-year growth of roughly 23% to 28%, driven largely by strong uptake of its Menhycia...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.